The antibacterial activity of teichomycin, a glycopeptide antibiotic similar to vancomycin, has been evaluated in vitro and compared with that of vancomycin. Test strains included 130 staphylococci and 132 streptococci, with representatives of the major currently recognized species or groups, and lesser numbers of clostridia, propionibacteria, and group JK bacteria. Teichomycin was found to be more active than vancomycin. Its minimum inhibitory concentration (MIC) was two-to fourfold lower than that of vancomycin with staphylococci and anaerobic bacteria, and two-to eightfold lower with streptococci. No significant differences were observed with group JK bacteria. For most strains tested, minimum bactericidal concentrations (MBCs) of both teichomycin and vancomycin either equalled or exceeded by twofold the respective MICs. Higher MBC-to-MIC ratios were obtained for enterococci and pneumococci with both antibiotics. Both teichomycin and vancomycin showed similar in vitro interactions with rifampin in combination tests. Neither antagonism nor (with very few exceptions) synergism occurred.
Teichomycin (originally called teichonmy'cin A2) is a bactericidal antibiotic recently obtained from Actinoplanes teichomyceticus (3, 21) . It is related to the glycopeptide group of antibiotics, whose major member is vancomycin, and also resembles the latter drug in the mode of inhibiting cell wall synthesis in gram-positive organisms (24) .
The aim of this study was to assess the in vitro antibacterial activity of teichomycin and to compare it with vancomycin. Moreover, since several reports have recently emphasized the successful treatment of staphylococcal endocarditis with a combination of vancomycin and rifampin (2, 11, 14, 20) , the in vitro interactions of teichomycin and rifampin and those of vancomycin and rifampin were also studied and compared.
The strains used in this study largely included conventional bacterial targets of vancomycin such as staphylococci and streptococci. Representatives of the major currently recognized species or groups of both organisms were tested. In addition, we investigated some strains of pathogens which have been reported to be susceptible to vancomycin, such as Clostridium perfringens (23) and Propionibacterium acnes (29) , or for which vancomycin has even been suggested as the drug of choice, such as Clostridium difficile (16, 25) and group JK bacteria (13, 22) . C. difficile has been clearly implicated as the causative agent of antimicrobial agentassociated pseudomembranous colitis (4, 12 Minimum bactericidal concentrations (MBCs) were determined by standard procedures (26) . Serial twofold broth dilutions of teichomycin and vancomycin (1 ml per tube) were prepared; concentrations up to 102 p.g/ml were assayed. The media used were MuellerHinton broth (Difco) for staphylococci, enterococci, and group JK bacteria; a 1:1 mixture of MuellerHinton broth and Todd-Hewitt broth (Oxoid Ltd., Basingstoke, England) for non-group D streptococci; and Schaedler broth (BBL) with vitamin K1 (0.1 p,g/ml) for anaerobes. One milliliter of the inoculum suspension (adjusted so as to contain ca. 106 CFU/ml) was added to each test tube. The tubes were incubated at 35°C for 20 h. For anaerobic bacteria, the anaerobic incubator mentioned above was used. One hundred microliters (10 samples of 10 ,ul) was drawn with a calibrated loop from the tubes showing no growth and streaked on the surface of plates containing brain heart infusion agar (Difco) with 5% defibrinated horse blood (for aerobic bacteria) or Schaedler agar with 10 ,ug of vitamin K1 per ml and 5% defibrinated sheep blood (for anaerobes). These plates were incubated at 35°C for 48 h under aerobic or anaerobic conditions, respectively. The MBC was read as the lowest antibiotic concentration which gave no visible growth in the subculture.
Antibiotic combinations. Combinations of teichomycin or vancomycin with rifampin were assessed by a standard checkerboard agar dilution method (18) . The test media, inoculation, incubation, and reading were as described above for MIC testing. Antibiotic interactions were interpreted as follows: Synergism, when the MIC of both drugs was at least one-fourth of the MIC of each drug alone. Antagonism, when inhibition occurred at concentrations exceeding the MIC of either drug.
RESULTS
MIC tests. All strains tested were susceptible to both teichomycin and vancomycin. The MIC defined as the threshold of susceptibility (6.4 ,uglml for both antibiotics) was recorded for one isolate (belonging to Staphylococcus xylosus) with teichomycin and for four isolates (one belonging to S. epidermidis, one to C. perfringens, and two to enterococci) with vancomycin. Lower MICs of both antibiotics were recorded for all other strains.
For the great majority of isolates tested, the MIC of teichomycin was found to be lower than that of vancomycin. The MIC range and the MICs that were inhibitory to 50 and 90%o of the organisms tested are shown in Tables 1 through   3 .
With most Staphylococcus isolates, the MIC of teichomycin was two-to fourfold lower than that of vancomycin. The greater activity of teichomycin was apparent both in the total number of isolates and in the individual species ( those recorded between the two drugs for staphFor most isolates, MBCs of both teichomycin ylococci were seen for most Streptococcus iso-and vancomycin either equalled or exceeded by lates (MICs of teichomycin were two-to eight-twofold the respective MICs. MBC-to-MIC rafold lower than those of vancomycin). tios higher than 2 were recorded for enterococci, Moreover, for some streptococcal groups, MICs pneumococci, and the C. perfringens strain testof teichomycin also appeared to be distributed ed. For the latter, an MBC-to-MIC ratio equal to over a wider range than those of vancomycin 8 was obtained with vancomycin, whereas no (Table 2) . difference between MBC and MIC occurred For the eight strains of Clostridium and one with teichomycin. For the three S. pneumoniae strain of P. acnes, the MICs of teichomycin strains tested, MBC-to-MIC ratios ranged from were found to be two-to fourfold lower than 4 to 16 with teichomycin and from 4 to 8 with those of vancomycin. Equal MICs of both drugs vancomycin. The highest MBC-to-MIC ratios were observed for the two remaining propioni-were obtained for enterococci, for which vancobacteria (Table 3) . mycin was not fully bactericidal even at the Significant differences were not observed in highest concentration tested (102.4 ,ug/ml) for the activities of teichomycin and vancomycin four strains out of five, and an MBC-to-MIC against group JK bacteria, as confirmed by the ratio as high as 64 was obtained for the remainidentical MIC range and MICs inhibitory to 50 ing strain. With teichomycin, MBC-to-MIC raand 90% of strains exhibited by the two antibiot-tios were equal to 64 for three isolates and to 4 ics ( differences between the in vitro interaction of teichomycin and rifampin and that of vancomycin and rifampin; (ii) antagonism did not occur; (iii) indifference was the prevalent response; (iv) synergism was a rare event, only observed for two staphylococcal isolates (one of S. aureus and one of S. hominis) with the teichomycin plus rifampin combination and for one isolate (the same S. aureus strain as above) with the vancomycin plus rifampin combination; (v) differences from species to species were not significant.
DISCUSSION
The development of new antibiotics such as teichomycin fromn the vancomycin group may be of special importance today. In fact, renewed attention is currently being focused on vancomycin after years when it was virtually unused because of its toxicity and obligatory intravenous administration. A number of recent reports have emphasized the great utility of vancomycin, alone or in combination with other antibiotics, in severe and life-threatening infections (6, 7, 11, 15) and its special efficacy against dangerous and multiply resistant newly recognized pathogens such as C. difficile, which responds to oral administration in pseudomembranous colitis (16, 25) , or group JK bacteria.
In this study, teichomycin has proved to be more inhibiting in vitro than vancomycin against the great majority of the strains tested. In another recent study (8) , carried-out by a different procedure and with many fewer strains, similar differences in the in vitro activity of teichomycin and vancomycin were reported for enterococci, whereas less marked differences than those reported here were obtained for staphylococci. For most isolates tested here, a greater activity of teichomycin was confirmed in the MBC tests. Also, for enterococci, for which a marked disparity between inhibiting and killing activity was observed (consistent with the tendency of these organisms to behave as tolerant to many bactericidal antibiotics [26] ), lower MBC-to-MIC ratios were obtained with teichomycin than with vancomycin. Altogether, the greater in vitro activity of teichomycin appears to be particularly significant in light of the results of early in vivo studies on this drug. Compared with vancomycin, it can be administered intramuscularly, has lower toxicity, and gives higher and more persistent serum levels in animals as well as in human volunteers (5; V. Arioli, personal communication).
The lack of both antagonism and synergism appears to be the main aspect of our in vitro investigation of the combinations of teichomycin and vancomycin with rifampin. In the absence of antagonism, the lack of synergism does not seem to be in contrast with the reported efficacy of combined therapy with vancomycin and rifampin (2, 11, 20) . The excellent entry of rifampin into phagocytic leukocytes (19) and suppression by vancomycin of the resurgence of rifampinresistant mutants might well explain (as also suggested by others [31] ) the therapeutic efficacy of this antimicrobial combination in the absence of a really synergistic drug interaction. The present findings show that the interaction of teichomycin and rifampin in vitro is similar to that of vancomycin and rifampin. Further in vivo studies are indicated to elucidate the possible advantages of teichomycin over vancomycin in combined administration with rifampin.
